INCRUSE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Incruse, and what generic alternatives are available?
Incruse is a drug marketed by Glaxo Grp England and is included in one NDA. There is one patent protecting this drug.
The generic ingredient in INCRUSE is umeclidinium bromide. There are two drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the umeclidinium bromide profile page.
DrugPatentWatch® Generic Entry Outlook for Incruse
Indicators of Generic Entry
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for INCRUSE?
- What are the global sales for INCRUSE?
- What is Average Wholesale Price for INCRUSE?
Summary for INCRUSE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Prices: | Drug price information for INCRUSE |
| DailyMed Link: | INCRUSE at DailyMed |
US Patents and Regulatory Information for INCRUSE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxo Grp England | INCRUSE ELLIPTA | umeclidinium bromide | POWDER;INHALATION | 205382-001 | Apr 30, 2014 | RX | Yes | Yes | 7,488,827 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
